Interim survival analysis of the randomized phase III GEMSTONE-302 trial: sugemalimab or placebo plus chemotherapy as first-line treatment for metastatic NSCLC

Efficacy and safety of pralsetinib in patients with advanced RET fusion-positive non–small cell lung cancer

Sugemalimab Monotherapy for Patients With Relapsed or Refractory Extranodal Natural Killer/T-Cell Lymphoma (GEMSTONE-201): Results From a Single-Arm, Multicenter, Phase II Study

GEMSTONE 304: A Phase 3 study of sugemalimab plus chemotherapy versus chemotherapy as first line treatment of patients with unresectable locally advanced, recurrent or metastatic esophageal squamous cell carcinoma (ESCC)

GEMSTONE-304: a phase 3 study of sugemalimab plus chemotherapy versus chemotherapy as first-line treatment of patients with unresectable locally advanced, recurrent or metastatic esophageal squamous cell carcinoma (ESCC)

Clinical efficacy of avapritinib in gastrointestinal stromal tumors (GISTs) with different KIT genotypes: post hoc analysis of the phase 1 NAVIGATOR and phase 1/2 CS3007-101 trials

Translational considerations in the development of CS5001, a PBD based ADC against ROR1, a tumor specific target

Efficacy and Safety of Avapritinib in Treating Unresectable or Metastatic Gastrointestinal Stromal Tumors: A Phase I/II, Open-Label, Multicenter Study